大鼠肝微粒体代谢研究槲皮素对CYP1A2,CYP2E1,CYP3A2活性的影响及抑制机制

摘要/Abstract

摘要： 目的体外代谢研究槲皮素对大鼠肝CYP1A2 , CYP2E1, 和CYP3A2 活性的影响，研究其抑制强度及抑制机制。方法 QU与底物共同温孵, HPLC检测底物特定的代谢产物生成量的变化反映对应亚酶的活性变化。比较槲皮素与酮康唑, 红霉素在相同浓度下对CYP3A2的抑制能力强弱。不同浓度槲皮素对CYP3A2和CYP2E1底物代谢产物生成双倒数直线的影响初步分析槲皮素可能的抑制机制。结果各HPLC检测方法线性相关系数均>0.9991, RSD均<8.4%,回收率91.1% - 107.6 %。槲皮素在体外0～8 μmol·L^-1诱导大鼠肝微粒体CYP1A2的活性达338.1%, 并抑制CYP2E1(49.2%), 和CYP3A2 (60.3%)。槲皮素对CYP3A2的抑制能力在酮康唑和红霉素之间。槲皮素竞争性抑制CYP3A2右美沙芬-N-脱甲基反应, 非竞争性抑制CYP2E1氯唑沙宗-6-羟化反应。结论槲皮素对多个CYP450亚酶有抑制作用, 它是有效的CYP3A竞争性抑制剂, 做为黄酮类植物雌激素, 槲皮素有分子结构的优势亦有对CYP450酶调控能力而具有未来抗肿瘤药物研究的潜力。

关键词: 槲皮素, 槲皮素, 槲皮素, 细胞色素P450, 细胞色素P450, 细胞色素P450, 肝微粒体, 肝微粒体, 肝微粒体, 高效液相色谱, 高效液相色谱, 高效液相色谱, 抑制剂, 抑制剂, 抑制剂

Abstract: Aim To assess the potential effect of quercetin (QU), an natural plant estrogen, on CYP1A2, CYP2E1, and CYP3A2 activities in rat liver microsomes; and to identify the magnitude of inhibitory effect and the probable inhibitory mechanism of QU. Methods QU and specific substrate were concurrently incubated, with HPLC detection of the substrate metabolites for data analysis. The magnitude of inhibitory effect of QU on CYP3A2 was compared with those of ketoconazole (Ket) and erythromycin (Ery). The mechanism of its inhibitory effect on CYP3A2 and CYP2E1 was derived from Lineweaver-Burk plots. Results HPLC methods were in good linear relationship with r>0.999 1. Relative standard deviations for intra-day and inter-day were<8.4%. Recovery of each analyte in the concentrations studied was between 91.1% and 107.6 %. QU (up to 8 μmol·L-1) showed potent induction to CYP1A2 (338.1% of the negative control)while inhibited CYP2E1 (49.2% of the negative control) and CYP3A2 (60.3% of the negative control) activity. The magnitude of inhibitory effect for QU on CYP3A2 was between those for Ket and Ery (Ket>QU>Ery). QU exhibited competitive inhibition of CYP3A2 dextromethorphan N-demethylation reaction and expressed noncompetitive inhibition of CYP2E1 chlorzoxazone-6-hydroxylation reaction. Conclusion HPLC assay has been validated with precision and accuracy. QU is an effective inhibitor of several CYP isoforms. It may cause relevant drug-drug interactions with CYP3A substrates. As a plant flavonoid, QU has potential not only in molecular advantage but also in CYP450 module capability for further application in cancer chemotherapy.

Key words: quercetin, quercetin, cytochrome P450, cytochrome P450, liver microsome, liver microsome, HPLC, HPLC, inhibitor, inhibitor

中图分类号:

Supporting: ^*Corresponding author. Tel.: 86-10-87788428

周江泉^*, 汤致强. 大鼠肝微粒体代谢研究槲皮素对CYP1A2,CYP2E1,CYP3A2活性的影响及抑制机制[J]. .

ZHOU Jiang-quan^*, TANG Zhi-qiang. Effect of Quercetin on CYP1A2, CYP2E1, CYP3A2 Activities and its Inhibitory Mechanism Studies in Rat Liver Microsomes[J]. .

参考文献

[1] Jacobs MN, Lewis DF. Steroid hormone receptors and dietary ligands: a selected review [J]. Proc Nutr Soc, 2002, 61 (1) : 105-122.
[2] Magee PJ, Rowland IR. Phyto-oestrogens, their mechanismof action : current evidence for a role in breast and prostate cancer [J]. Br J Nutr, 2004, 91 (4) : 513-531.
[3] Ferguson PJ, Kurowska E, Freeman DJ, et al. A flavonoid fraction from craneberry extract inhibits proliferation of human tumor cell lines [J]. J Nutr, 2004, 134 (6) : 1529-1535.
[4] Mertens-Talcott SU, Percival SS. Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells [J]. Cancer Lett, 2005, 218 (2) : 141-151.
[5] Williams SN, Shih H, Guenette DK, et al. Comparative studies on the effects of green tea extracts and individual tea catechins on human CYP1A gene expression [J]. Chem Biol Interact, 2000, 128 (3) : 211-229.
[6] von Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba [J]. J Pharm Pharmacol, 2004, 56 (8) : 1039-1044.
[7] Vengurlekar SS, Heitkamp J, McCush F, et al. A sensitive LC-MS/MS assay for the determination of dextromethorphan and metabolites in human urine-application for drug interaction studies assessing potential CYP3A and CYP2D6 inhibition [J]. J Pharm Biomed Anal, 2002, 30 : 113-124.
[8] Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism2based inactivator of cytochrome P450 3A4 [J]. Life Sci, 2000, 67 (25) : 3103-3112.
[9] Testino SAJr, Patonay G. High2throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography2tandem mass spectrometry [J]. J Pharm Biomed Anal, 2003, 30 (5) : 1459-1467.
[10] Paul LD, Springer D, Staack RF, et al. Cytochrome P450 isoforms involved in rat liver microsomal metabolism of californine and protopine [J]. Eur J Pharmacol, 2004, 485 (123) : 69-79.
[11] Peng SX, Barbone AG, Ritchie DM. High-throughput cytochrome P450 inhibition assays by ultrafast gradient liquid chromatography with tandem mass spectrometry using monolithic columns [J]. Rapid Commun Mass Spectrom, 2003, 17 (6) : 509-518.
[12] Cox SK, Hamner T, Bartges J. Determination of 6-hydroxychlorzoxazone and chlorzoxazone in porcine microsome samples [J]. J Chromatogr B, 2003, 784 (1) : 111-116.
[13] Lutz ES, MarklingME, Masimirembwa CM. Monolithic silica rod liquid chromatography with ultraviolet or fluorescence detection for metabolite analysis of cytochrome P450 marker reactions [J]. J Chromatogr B, 2002, 780 (2) : 205-215.
[14] Zhou JQ, Tang ZQ, Zhang JN, et al. Metabolism and effect of para-toluene-sulfonamide (PTS) on rat liver microsome cytochrome P450 from in vivo and in vitro studies [J]. Acta Pharmacol Sin, 2006, 27 : (in press).
[15] Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes [J]. Chem Biol Interact 2004, 150 (2) : 137-147.
[16] Niwa T, Shiraga T, Hashimoto T, et al. Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes [J]. Biol Pharm Bull, 2004, 27 (3) : 415-417.
[17] Rahden-Staron I, Czeczot H, Szumilo M. Induction of rat liver cytochrome P450 isoenzymes CYP1A and CYP2B by different fungicides, nitrofurans, and quercetin [J]. Mutat Res, 2001, 498 (1-2) : 57-66.
[18] Zhou JQ, Tang ZQ. Cytochrome P450 directed prodrug activation therapy in the research of cancer enzymology [J]. J Chin Pharm Sci, 2005, 14 (1) : 1-9.
[19] Reid JM, Kuffel MJ, Miller JK. Metablic activation of dacarbazine by human cytochrome P450 : the role of CYP1A1, CYP1A2, and CYP2E1 [J]. Clin Cancer Res, 1999, 5 (8) : 2192-2197.